Navigation Links
Micropharma announces timeline to commercial launch of world's first ingestible gastrointestinal sampling device
Date:4/26/2013

MONTREAL, April 26, 2013 /PRNewswire-iReach/ -- Micropharma Limited, a pioneer in the development of innovative and effective products based on the human microbiome, today announced that after three years of development it has a timeline for launch of its ingestible gastrointestinal sampling technology.  The company released its plans to launch the device in late 2014 commercially for research and development use and later for specific clinical applications.  Micropharma has been developing the device for three years and in the last year has expedited the project by partnering with StarFish Medical a medical device development company that offers a full complement of design and manufacturing solutions. The partnership will see StarFish Medical improve and finalize the design of the autonomous multiple sample acquisition and localization technologies, design for manufacture, produce initial devices, as well as to engineer for cost effectiveness.

(Photo: http://photos.prnewswire.com/prnh/20130426/CG02095)

Micropharma's chief scientific officer Dr. Mitchell Jones commented on the advantages of sampling the GI mucosa over the evaluation of fecal samples by saying "our ingestible pill can sample the mucosa at pre-determined locations throughout the GI tract, including the small intestine.  The device is programmable, acts autonomously and can take multiple, large, discrete samples that can be evaluated for human genomic, metabolomic and human gut microbiome data; of immediate and specific interest is to improve samples for microbiome research" he commented further that "protecting the intellectual property was an important part of the commercial development process and we are pleased to have recently filed an international PCT patent application" and that "sampling the gastrointestinal tract allows for site-specific analysis of the bacterial populations and metabolites present at the mucosal surface is a distinct advantage over the evaluation of fecal samples for many applications".

Manipulation of the gut microbiome is becoming an important way to treat immune, gastrointestinal and metabolic disease.  Probiotic therapies affecting the human gut microbiome have gained regulatory approval and are now included as part of clinical guidelines for a wide range of indications.  Further, there are now a number of microbiome focused companies actively developing microbiome based diagnostics, identifying uses for small molecules acting through the microbiome and developing GMO stains to affect the microbiome.  The pharmaceutical, consumer health and food industries are each attracted to microbiome focused solutions to human health issues and are impressed by the opportunities brought forth by a device capable of non-invasive sampling the gut microbiome.  To prove probiotic efficacy, support mechanisms of action, discover new and efficacious strains, develop new diagnostic/prognostics and ultimately to support future claims around microbiome products requires definitive information from relatively inaccessible sites within the human GI tract.  This information will open the door to personalized medicine, where diagnostic analysis of the microbiome will provide invaluable information on the likelihood of responses to probiotic and drugs.

The development of Micropharma's ingestible GI sampling device helps position the company as a world leader in human microbiome research and product development.  This enabling technology provides a distinct advantage through the acquisition and analysis of samples previously inaccessible, provide additional survival and mechanistic data to support the development of probiotic products and generate near-term revenue for the company through sales of research and commercial devices and out-licensing of specific aspects to other GI medical device companies.

About Micropharma Limited
Micropharma is a Canadian biotechnology company focused on human health through the microbiome. The company applies a unique approach, ProSelect, to the discovery and commercialization of novel products based on the human microbiome for the diagnosis and treatment of metabolic diseases.  Micropharma works on disease specific products with clear microbiome related mechanisms, and links to biomarkers that are associated with improving human health.  Micropharma is developing diagnostics and oral biologic therapies in the area of metabolic disease including hypercholesterolemia, metabolic syndrome, obesity, and diabetes.  For more info go to www.micropharma.net.

Media Contact:

Mitchell Jones , MD, PhD Micropharma Limited, 514-927-5333, mitchell@micropharma.net



News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Micropharma Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Micropharma Convenes Expert Roundtable on New Role for Probiotics in Cardiovascular Disease in time for National Cholesterol Education Month
2. Law Office of Brodsky & Smith, LLC Announces Investigation of PROLOR Biotech, Inc.
3. Probiotic Acne Treatment, Probiotic Action Announces Revolutionary Portable Acne Treatment
4. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
5. Japan Bioinformatics Announces Release of a Case Study on Detecting SNPs and Short INDELs
6. Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
7. SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
8. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
9. Plandai Biotechnology, Inc. Announces Shipment Of First Machinery To South African Production Facility
10. White Mountain Process Announces Sanitary Autoclave Style Pharmaceutical Agitator
11. InstantGMP Announces Release of Unique Electronic Batch Record Software as a Service for Just $99/mo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Eisai ... 3 open-label two-year study of rufinamide, which were ... American Epilepsy Society (AES) held from December 2-6 ... of final two-year safety, tolerability and cognitive data ... rufinamide experienced similar safety and tolerability profiles, cognitive ...
(Date:12/4/2016)... ... December 03, 2016 , ... Microbial genomics ... impact grant award has been made to Dr. Renato Polimanti of Yale University ... on the oral microbiome. Grant proposals have been vetted by the company’s scientific ...
(Date:12/2/2016)... COLD SPRING HARBOR, N.Y. , Dec. 2, 2016 /PRNewswire/ ... Spring Harbor Laboratory,s (CSHL) 11th Double Helix Medals dinner ( DHMD ). ... History (AMNH) in New York City ... Vagelos for their contributions, respectively, to health and medicine ... honored Muhammad Ali in 2006, the event has ...
(Date:12/2/2016)... , Dec 2, 2016 Research ... report "Nanobiotechnology Applications, Markets and Companies" to their ... , , ... nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology ... from formulations for optimal delivery to diagnostic applications in clinical ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):